Cancer drug developer brings in $52M from stock sale

Verastem, which specializes in drugs that target cancer stem cells, secured at least $52 million from a public stock offering. The Cambridge, Mass.-based firm will use the money mainly to support studies of its lead drug candidates for cancer.

View Full Article in:

American City Business Journals · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN